GLORIA-AF: Global Registry on Long-Term Oral Anti-thrombotic Treatment In Patients With Atrial Fibrillation (Phase II/III-India and Switzerland)
Active, no longer recruiting
Phase of Trial: Phase IV
Latest Information Update: 08 Mar 2017
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Atrial fibrillation; Stroke
- Focus Therapeutic Use
- Acronyms GLORIA-AF
- Sponsors Boehringer Ingelheim
- 04 Dec 2016 The results were presented at the American Society of Hematology (ASH) Annual Meeting, as reported by Boehringer Ingelheim media release.
- 04 Dec 2016 Results published in the Boehringer Ingelheim Media Release
- 30 Aug 2016 Results from this trial presented at the ESC Congress 2016, as reported by Boehringer Ingelheim media release.